Differential effects of neurodegeneration biomarkers on subclinical cognitive decline.

Merluzzi, A., N. Vogt, D. Norton, E. Jonaitis, L. Clark, C. Carlsson, S. Johnson, S. Asthana, K. Blennow, H. Zetterberg, and B. Bendlin. “Differential Effects of Neurodegeneration Biomarkers on Subclinical Cognitive Decline.”. Alzheimer’s & Dementia (New York, N. Y.), Vol. 5, 2019, pp. 129-38.

Neurodegeneration appears to be the biological mechanism most proximate to cognitive decline in Alzheimer’s disease. We test whether t-tau and alternative biomarkers of neurodegeneration-neurogranin and neurofilament light protein (NFL)-add value in predicting subclinical cognitive decline.

DOI: 10.1016/j.trci.2019.02.004

PubMed: 31011623